



Danger from the Wild: HIV, Can We Conquer It?

David Baltimore
Professor, California Institute of
Technology

Part III

The Grand Challenge: Engineering Immunity


Reprogramming the Immune System using Gene Therapy

- What is needed is a vaccine or therapy that brings into play antibodies or other anti-viral proteins
- Vectors could be used to bring genes encoding such proteins into the immune system

Reprogramming the Immune System using Gene Therapy


- Such an approach liberates us to use modern protein design methods to create antibody-like proteins that can be programmed into the immune system.
- The vectors will be put into stem cells which should then develop into the cells that make antibody, B cells.

Overall Goal for the Project




To direct blood stem cells to develop into B cells capable of making therapeutic molecules against HIV and other pathogens.

General Approach



- The immune system is remarkable but not perfect
 - Repertoire of antibodies is large but not infinite, there are holes
 - Even if repertoire includes a particular antibody, we may not be able to elicit the response with a available antigen

General Approach




- So we have as a goal to engineer immune cells to do new, valuable things, such as making antibodies or T cells or intracellular immunogens like RNAi
- This is the Engineering Immunity project

Specific Approaches

Have taken 3 specific approaches:


- Intracellular immunization using RNAi
 - Mainly directed against HIV
- Engineering T cells to react with tumor antigens (almost in Phase I trial)
- Engineering B cells to make prespecified monoclonal antibodies or antibody-like proteins, targeting HIV

General Methodology




- All three have a common methodology: to use retrovirus vectors to program particular abilities into hematopoietic stem cells that give rise to B cells and T cells
- Thus, this is a gene therapy approach to stem cell modification

“Instructive Immunotherapy”




Program T Cells for Anti-tumor Immunity



Life-long supplies of tumor-specific lymphocytes







Target tumors ← Lymphocytes

Our General Strategy for Modifying B cells:



Life-long supplies of anti-HIV neutralizing antibodies (NAb)

Target HIV ← Lymphocytes



To Take This to Humans

- Requires making blood stem cell transplant a routine, safe and reasonably-priced therapeutic intervention or developing targeted gene delivery in vivo
- Requires showing that gene therapy is generally safe and there have been doubts because of cancer in 3 out of 11 children treated for XSCID
 - Could design in safety features or use lentivirus (HIV)-based vectors

To Take This to Humans

- Requires much logistic work to get antibody secretion
- Potential benefits are enormous: cancer, HIV, other infectious diseases

Therapy → Vaccine

- So far, we conceive of a therapy as the end result of the engineering immunity initiative
- However, with vectors targeted to blood stem cells in living animals, a vaccine becomes a possible goal
- In any case, my overall message is: no harm in thinking big when thinking small has been so uniformly problematic

Acknowledgements



BILL & MELINDA
GATES foundation

David Baltimore Lab
Lili Yang

Pamela Bjorkman Lab

Skirball Foundation



Pin Wang Lab